[ET Net News Agency, 10 June 2021] Huatai raised its target price for Kintor
Pharmaceutical (09939) to HK$88.19 from HK$21.08 and maintained its "buy" rating.
The research house said it is positive on the potential of proxalutamide and GT90001 in
respective COVID-19 and HCC treatments and expects Kintor to lead the transition from
biotech to biopharma in China, supported by potential cash flow accumulation. (RC)